Chronic Kidney Disease MBD 3

1,979 views

Published on

Chronic kidney Disease- Mineral Bone Disease Part 3

Published in: Education, Health & Medicine
0 Comments
4 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
1,979
On SlideShare
0
From Embeds
0
Number of Embeds
5
Actions
Shares
0
Downloads
0
Comments
0
Likes
4
Embeds 0
No embeds

No notes for slide

Chronic Kidney Disease MBD 3

  1. 1. CKD MBD- 3 Dr. Sandeep G Huilgol MBBS., DNB (Internal Medicine)., MMedSci(Nephrology)
  2. 2. Definition A systemic disorder of mineral and bone metabolism due to CKD manifested by either one or a combination of the following:• Abnormalities of calcium, phosphorus, PTH, or vitamin D metabolism• Abnormalities in bone turnover, mineralization, volume, linear growth, or strength• Vascular or other soft-tissue calcification Reference: KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of CKD-MBD(Kidney Int. 2009; 76[suppl 113])
  3. 3. BONE DISEASE IN CKDBone Biology:• Cancellous bone is present in the epiphyses, and cortical bone, in the shafts of long bones.• Bone consists of crosslinked type 1 collagen fibers (90%) and proteoglycans, osteopontin, osteocalcin, osteonectin, and other noncollagenous proteins• Cells in bone are cartilage cells, osteoblasts, and osteoclasts• Mesenchymal cells in bone marrow are differentiated to form osteoprogenitor cells and eventually mature osteoblasts• After bone formation, osteoblasts may undergo apoptosis or become a part of mineralized bone as osteocytes
  4. 4. • Osteoclasts are formed from hematopoietic cells, fusing at bone to become multinucleated cells that reabsorb bone using enzymes• At any time, 20% of bone surface undergoes remodeling, a process that takes 3-6 months• Phases of bone remodeling are osteoclast resorption, reversal, maturation of osteoblasts, filling of lacunae with osteoid or unmineralized bone, mineralization, and finally a quiescent stage• Bones are chosen to undergo remodeling through the osteoprotegerin (OPG) and the RANK (receptor activator of nuclear factor-B) system regulated by hormones (PTH, calcitriol, estrogen, and glucocorticoids, as well as cytokines and interleukins)
  5. 5. Renal Osteodystrophy• The term is specific to bone pathologic states in patients with CKD and is a component of CKD-MBD• Renal osteodystrophy is assessed by bone biopsy at the trabecular bone at iliac crest by tetracycline labelling• Patients are given tetracycline 3 weeks and 3-5 days before bone biopsy• Tetracycline binds to hydroxyapatite and labels bone for visualization by fluorescence microscopy• The amount of bone formed between the 2 tetracycline labels is used to calculate bone turnover
  6. 6. • Three key parameters are used to assess bone turnover, mineralization, and volume; TMV system(Moe et al. Kidney Int. 2006;69(11):1945-1953.).• Biomarkers such as PTH and bone alkaline phosphatase are only modestly predictive of underlying bone histology, but currently are the best available noninvasive tools for the assessment of renal osteodystrophy• Overall, impaired bone quality (altered architecture, remodeling, mass, and volume) is seen in CKD• This can be superimposed on pre-existing age-related changes in bone, such as loss of bone mass due to osteoporosis• This translates to an increased prevalence of fractures in dialysis patients compared with age-matched general population
  7. 7. Normal Bone: Goldner Masson trichrome stain shows mineralized lamellar bone in blue andadjacent nonmineralized osteoid in red-brown. Osteoid usually comprises less than 25percent of bone surfaces. The cellular area between the osseous structures is the marrowspace. Right panel: Villanueva-stained section viewed under polarized light following time-spaced tetracycline labeling. Osteoid appears orange, mineralized bone is green, andtetracycline markers appear as luminescent yellow-green bands within bone and beneathosteoid (arrow). The distinct dual bands represent active mineralized bone formation.©2011 UpToDate: L Darryl Quarles.
  8. 8. Osteitis fibrosa due to severe secondary hyperparathyroidism. Left panel: GoldnerMasson trichrome stain shows an increased number of multinucleate osteoclasts at theresorptive surfaces (arrow) and extensive bone marrow fibrosis (as shown by the lightblue staining of the marrow) replacing normal marrow elements. The increasedresorptive activity results in a thin and scalloped appearance to mineralized trabecularbone (blue). Right panel: Tetracycline labeling reveals a marked increase both inosteoid (orange-red staining) and in new bone formation (two distinct yellow-greenbands below the majority of orange-red stained osteoid surfaces
  9. 9. Mixed Uremic Osteodystrophy: Features of both osteitis fibrosa and low turnoverosteomalacia. Left panel: Trichrome stain reveals increased numbers of multinucleateosteoclasts (short arrow) as expected in osteitis fibrosa plus a marked increase in adjacentnonmineralized osteoid in red-brown (long arrow). Right panel: Tetracycline labelingdemonstrates impaired mineralization as evidenced by diffuse tetracycline deposition (yellowstain, short arrow) and the absence of tetracycline at some bone forming surfaces as in thelower left quadrant (long arrow).
  10. 10. Low turnover osteomalacia: Left panel: Goldner Masson trichrome stain showsthin mineralized bone in blue surrounded by wide unmineralized osteoid with nocellular activity in orange-brown. There are no osteoblasts or erosive surfacespresent. Right panel: Villanueva stain following tetracycline labeling and viewedunder fluorescent light reveals a marked increase in width of the osteoid seams(orange) with no evidence of mineralization of new bone (which would result intetracycline deposition, as manifested by a yellow line appearing beneath theosteoid seams).
  11. 11. Adyanamic Bone disease: This disorder is characterized by reductions inbone formation and bone resorption that are manifested histologically bythin osteoid seams (red lines at the bone surface; arrows) and little or noevidence of cellular activity.
  12. 12. Next Class:Other manifestations of CKD-MBD and treatment
  13. 13. THANK YOU

×